Clincosm LogoSign in Get a demo

The Lymphocyte/Neutrophil Ratio as a Prognostic Index for Short Term Outcome in the ICU Admitted COVID-19 Adult Patients

Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT04817397
Collaborator
(none)
100
Enrollment
1
Location
5.4
Actual Duration (Months)
18.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

  1. ry outcome includes the correlation between lymphocyre /neurtophll ratio (LNR) and mortality rate during hospital stay in the ICU admitted COVID 19 patients.

  2. ry outcome(s) include the LNR and its correlation with ICU stay, the need for mechanical ventilation, renal impairment.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In December 2019,the COVID-19 virus has been mainly breaking out in Wuhan in China as pneumonia affecting patients . Common clinical features During hospitalization started to appear including acute respiratory infection , inflammatory reaction , fever, pneumonia, cough, fatigue , anosmia .

    The patient known suspected if he has a clinical picture of viral pneumonia, exposure history, and radiographic findings [CT] or [MRI] chest consistent with COVID-19 pneumonia. the gold standard and the Final diagnosis (PCR) positivity for the presence of coronavirus .

    The immune response to respiratory infection causes neutrophils to collect inside the lung especially the alveoli. Neutrophils aggregation may lead to collateral tissue damage and cytotoxicity. According to Previous studies apoptosis of lymphocytes occurred due to the release of anti-inflammatory cytokines resulting in lymphopenia. high levels of circulating neutrophils have been demonstrated in COVID-19 patients(

    A lot of literatures and studies have demonstrated the value of what is called neutrophil/ lymphocyte ratio (LNR) as a simple prognostic ratio correlated to morbidity and mortality. Up to our knowledge, there is no study utilized such ratio in COVID-19 ICU admitted patients, so that, this study has been built

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Lymphocyte/Neutrophil Ratio as a Prognostic Index for Short Term Outcome in the ICU Admitted COVID-19 Adult Patients
    Actual Study Start Date :
    Mar 20, 2021
    Actual Primary Completion Date :
    Jul 30, 2021
    Actual Study Completion Date :
    Aug 30, 2021

    Outcome Measures

    Primary Outcome Measures

    1. The Lymphocyte/neutrophil ratio [up to 30 days]

      The Lymphocyte/neutrophil ratio as a prognostic index for short term outcome in the ICU admitted COVID-19 adult patients

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Adult patients (aged ≥18 years)

    2. Patients who need non-invasive ventilation (NIV or CPAP) or invasive ventilation (intubation)

    Exclusion Criteria:

    1. Previous diagnosis of severe liver or kidney failure.

    2. Patients with Human Immunodeficiency Virus (HIV) infection.

    3. Patients with previous hematological diseases (Leukemia) that condition alterations in blood counts.

    4. Consumption of treatments with any type of immunosuppressants prior to admission that conditions low lymphocytes.

    5. Patients with bone marrow depression.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Assuit University Assiut Egypt

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Emad Zarief , MD, Professor Emad Zarief kamel, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04817397
    Other Study ID Numbers:
    • ICU admitted COVID-19 patients
    First Posted:
    Mar 26, 2021
    Last Update Posted:
    Oct 12, 2021
    Last Verified:
    Oct 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Oct 12, 2021